[SCHEDULE 13G/A] Korro Bio, Inc. SEC Filing

Rhea-AI Filing Summary

Korro Bio, Inc. Schedule 13G/A shows Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin jointly report beneficial ownership of 277,966 common shares, equal to 2.96% of the company's outstanding common stock. The filers report no sole voting or dispositive power and shared voting and dispositive power for the full amount, and include a certification that the shares were not acquired to change or influence control. The percentage is calculated using 9,390,492 shares outstanding as referenced in the issuer's disclosure.

Positive

• Transparent disclosure of beneficial ownership: 277,966 shares disclosed with explicit percentage (2.96%).
• Passive filing under Schedule 13G with certification that shares were not acquired to influence control, which clarifies intent.

Negative

• None.

Insights

Securities Analyst

TL;DR: Deep Track reports a 2.96% passive stake (277,966 shares); this is a routine disclosure with limited immediate market impact.

The Schedule 13G/A format and the included certification signal a passive investment posture rather than an activist intent. The stake size is below 5% and the filing shows shared voting and dispositive power only, which typically means no unilateral control. Investors should view this as a transparency filing rather than a change in corporate control or strategy.

Corporate Governance Expert

TL;DR: Joint filing clarifies ownership and responsibilities among reporting persons; certification reduces takeover or control concerns.

The joint filing statement assigns responsibility for timely and accurate amendments to the reporting group while limiting each party's liability for others' information except where knowledge exists. The explicit statement that the shares were not acquired to influence control reinforces the passive classification under Rule 13d-1, making this disclosure governance-related but not a governance risk trigger.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Korro Bio, Inc.

(Name of Issuer)

Common stock, par value $0.001 per share

(Title of Class of Securities)

500946108

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 500946108

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 277,966.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 277,966.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

277,966.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.96 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 500946108

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 277,966.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 277,966.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

277,966.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.96 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 500946108

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 277,966.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 277,966.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

277,966.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.96 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Korro Bio, Inc.
(b)	Address of issuer's principal executive offices: 60 First Street, 2nd Floor, Suite 250, Cambridge, MA 02141
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)	Title of class of securities: Common stock, par value $0.001 per share
(e)	CUSIP No.: 500946108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 277,966
(b)	Percent of class: 2.96%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 277,966
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 277,966
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	08/14/2025

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	08/14/2025

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	08/14/2025

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Ordinary Shares as of August 14, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined based on 9,390,492 Common Stock outstanding as of May 5, 2025, according to the issuer's Form 10-Q filed with the SEC on May 7, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin

FAQ

How many Korro Bio (KRRO) shares does Deep Track report owning?

The filing reports 277,966 shares beneficially owned by the reporting persons.

What percentage of KRRO does the 277,966 shares represent?

The reported amount represents 2.96% of Korro Bio's outstanding common stock as presented in the filing.

Does the filing indicate that Deep Track intends to influence Korro Bio's control?

No. The Schedule 13G/A includes a certification stating the securities were not acquired to change or influence control, indicating a passive position.

What voting and dispositive powers are reported for these KRRO shares?

The filers report 0 shares with sole voting or sole dispositive power and 277,966 shares with shared voting and shared dispositive power.

On what share count is the 2.96% figure based?

The percentage is calculated using 9,390,492 common shares outstanding, as referenced in the filing incorporated by the exhibit.